Tumor microenviroment and hepatocellular carcinoma metastasis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue SUPPL 1, 2013, Pages 43-48

  Wang, Hongyang ^a,b   Chen, Lei ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Tumor metastasis; Tumor microenviroment

Indexed keywords

COLONY STIMULATING FACTOR 1; CYCLIN A; CYCLIN D1; CYCLINE; CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; INTERLEUKIN 6; VASCULOTROPIN;

B CELL LYMPHOMA; CELL INVASION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MESENCHYMAL STEM CELL; METASTASIS; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; STELLATE CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; TUMOR MICROENVIRONMENT;

EID: 84880411633     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12091     Document Type: Review

References (82)

1. Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin. Cancer Biol. 2011; 21: 35-43.
2. Leonardi GC, Candido S, Cervello M etal. The tumor microenvironment in hepatocellular carcinoma (review). Int. J. Oncol. 2012; 40: 1733-1747.
3. Vidal-Vanaclocha F. The prometastatic microenvironment of the liver. Cancer Microenviron. 2008; 1: 113-129.
4. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006; 6: 392-401.
5. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 2000; 275: 2247-2250.
6. Dubuisson L, Lepreux S, Bioulac-Sage P etal. Expression and cellular localization of fibrillin-1 in normal and pathological human liver. J. Hepatol. 2001; 34: 514-522.
7. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 2008; 88: 125-172.
8. Coulouarn C, Corlu A, Glaise D etal. Hepatocyte-stellate cell crosstalk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res. 2012; 72: 2533-2542.
9. Jia YL, Shi L, Zhou JN etal. Epimorphin promotes human hepatocellular carcinoma invasion and metastasis through activation of focal adhesion kinase/extracellular signal-regulated kinase/matrix metalloproteinase-9 axis. Hepatology 2011; 54: 1808-1818.
10. Xia Y, Chen R, Ye SL, Sun R, Chen J, Zhao Y. Inhibition of T-cell responses by intratumoral hepatic stellate cells contribute to migration and invasion of hepatocellular carcinoma. Clin. Exp. Metastasis 2011; 28: 661-674.
11. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124: 263-266.
12. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-217.
13. Zhu XD, Zhang JB, Zhuang PY etal. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J. Clin. Oncol. 2008; 26: 2707-2716.
14. Budhu A, Forgues M, Ye QH etal. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006; 10: 99-111.
15. Zhang W, Zhu XD, Sun HC etal. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and anti-angiogenic effects. Clin. Cancer Res. 2010; 16: 3420-3430.
16. Sander LE, Trautwein C, Liedtke C. Is interleukin-6 a gender-specific risk factor for liver cancer? Hepatology 2007; 46: 1304-1305.
17. Lai JJ, Lai KP, Chuang KH etal. Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression. J. Clin. Invest. 2009; 119: 3739-3751.
18. Luedde T, Trautwein C. Intracellular survival pathways in the liver. Liver Int. 2006; 26: 1163-1174.
19. Ye QH, Qin LX, Forgues M etal. Predicting hepatitis B virus-positive meta-static hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat. Med. 2003; 9: 416-423.
20. Wu K, Kryczek I, Chen L, Zou W, Welling TH. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res. 2009; 69: 8067-8075.
21. Sun BS, Ye QH, Ren N etal. Lentiviral-mediated silencing of Osteopontin through RNA interference suppresses invasiveness and tumorigenicity of liver cancer cells. Hepatology 2008; 48: 1834-1842.
22. Xue YH, Zhang XF, Dong QZ etal. Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma. Hepatology 2010; 52: 2012-2022.
23. Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol. Sci. 2008; 103: 4-13.
24. DeNardo DG, Barreto JB, Andreu P etal. CD4 (+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16: 91-102.
25. Langowski JL, Kastelein RA, Oft M. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol. 2007; 28: 207-212.
26. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 2006; 90: 1-50.
27. Woo HG, Park ES, Cheon JH etal. Gene expression-based recurrence prediction of hepatitis B virus -related human hepatocellular carcinoma. Clin. Cancer Res. 2008; 14: 2056-2064.
28. Yakirevich E, Resnick MB. Regulatory T lymphocytes: pivotal components of the host antitumor response. J. Clin. Oncol. 2007; 25: 2506-2508.
29. Gallimore AM, Simon AK. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene 2008; 27: 5886-5893.
30. Fu J, Xu D, Liu Z etal. Increased regulatory T cells correlate with CD8 T cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-2339.
31. Chen KJ, Lin SZ, Zhou L etal. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS ONE 2011; 6: e24671.
32. Gao Q, Qiu S-J, Fan J etal. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 2007; 25: 2586-2593.
33. Gao Q, Zhou J, Wang XY etal. Infiltrating memory/senescent T cell ratio predicts extrahepatic metastasis of hepatocellular carcinoma. Ann. Surg. Oncol. 2012; 19: 455-466.
34. Cai L, Zhang Z, Zhou L etal. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin. Immunol. 2008; 129: 428-437.
35. Ghiringhelli F, Ménard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol. Rev. 2006; 214: 229-238.
36. Bergmann C, Wild CA, Narwan M, Lotfi R, Lang S, Brandau S. Human tumor-induced and naturally occurring Treg cells differentially affect NK cells activated by either IL-2 or target cells. Eur. J. Immunol. 2011; 41: 3564-3573.
37. Chuang WL, Liu HW, Chang WY. Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion. Cancer 1990; 65: 926-930.
38. Tatsumi T, Takehara T, Yamaguchi S etal. Intrahepatic delivery of -galactosylceramide-pulsed dendritic cells suppresses liver tumor. Hepatology 2007; 45: 22-30.
39. Miyagi T, Takehara T, Tatsumi T etal. Concanavalin A injection activates intrahepatic innate immune cells to provoke an antitumor effect in murine liver. Hepatology 2004; 40: 1190-1196.
40. Wintermeyer P, Cheng C, Gehring S etal. Invariant natural killer T cells suppresses the neutrophil inflammatory response in a mouse model of cholestatic liver damage. Gastroenterology 2009; 136: 1048-1059.
41. Laso FJ, Madruga JI, Giron JA etal. Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver dis-ease but not active ethanol consumption. Hepatology 1997; 25: 1096-1100.
42. Saibara T, Maeda T, Miyazaki M, Onishi S, Yamamoto Y. Depressed immune function in patients with cirrhosis before emergence of hepatocellular carcinoma. Hepatology 1993; 18: 315-319.
43. Subleski JJ, Hall VL, Back TC, Ortaldo JR, Wiltrout RH. Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver. Cancer Res. 2006; 66: 11005-11012.
44. Wallace ME, Smyth MJ. The role of natural killer cells in tumor control-effectors and regulators of adaptive immunity. Springer Semin. Immunopathol. 2005; 27: 49-64.
45. Crowe NY, Coquet JM, Berzins SP etal. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 2005; 202: 1279-1288.
46. Bricard G, Cesson V, Devevre E etal. Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J. Immunol. 2009; 182: 5140-5151.
47. Li GC, Ye QH, Xue YH etal. Human mesenchymal stem cells inhibit metastasis of a hepatocellular carcinoma model using the MHCC97-H cell line. Cancer Sci. 2010; 101: 2546-2553.
48. Jing Y, Han Z, Liu Y etal. Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. PLoS ONE 2012; 7: e43272.
49. Lee D, Chung YH, Kim JA etal. Transforming growth factor beta 1 overexpression is closely related to invasiveness of hepatocellular carcinoma. Oncology 2012; 82: 11-18.
50. Mima K, Okabe H, Ishimoto T etal. CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res. 2012; 72: 3414-3423.
51. Bi Q, Tang S, Xia L etal. Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS ONE 2012; 7: e40169.
52. Thelen A, Scholz A, Benckert C etal. VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma. Int. J. Cancer 2008; 122: 2471-2481.
53. Wu F, Yang LY, Li YF, Ou DP, Chen DP, Fan C. Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma. Hepatology 2009; 50: 1839-1850.
54. Ng KT, Qi X, Kong KL etal. Overexpression of matrix metalloproteinase-12 (MMP-12) correlates with poor prognosis of hepatocellular carcinoma. Eur. J. Cancer 2011; 47: 2299-2305.
55. Chen JS, Huang XH, Wang Q etal. Sonic hedgehog signaling pathway induces cell migration and invasion through focal adhesion kinase/AKT signaling-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9 in liver cancer. Carcinogenesis 2012 [Epub ahead of print].
56. Neaud V, Faouzi S, Guirouilh J etal. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology 1997; 26: 1458-1466.
57. Muñoz U, Puche JE, Hannivoort R, Lang UE, Cohen-Naftaly M, Friedman SL. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1. Mol. Cancer Res. 2012; 10: 1216-1227.
58. Ogunwobi OO, Liu C. Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin. Exp. Metastasis 2011; 28: 721-731.
59. Tan S, Li R, Ding K, Lobie PE, Zhu T. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett. 2011; 585: 2229-2234.
60. Wang YC, Xu GL, Jia WD etal. Estrogen suppresses metastasis in rat hepatocellular carcinoma through decreasing interleukin-6 and hepatocyte growth factor expression. Inflammation 2012; 35: 143-149.
61. De Maria N, Manno M, Villa E. Sex hormones and liver cancer. Mol. Cell. Endocrinol. 2002; 193: 59-63.
62. Giannitrapani L, Soresi M, La Spada E etal. Sex hormones and risk of liver tumor. Ann. N. Y. Acad. Sci. 2006; 1089: 228-236.
63. Nagasue N, Yu L, Yukaya H. Androgen and oestrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: impact on intrahepatic recurrence after hepatic resection. Br. J. Surg. 1995; 82: 542-547.
64. Xu H, Wei Y, Zhang Y etal. Oestrogen attenuates tumour progression in hepatocellular carcinoma. J. Pathol. 2012; 228: 216-229.
65. Ma WL, Hsu CL, Yeh CC etal. Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology 2012; 56: 176-185.
66. Chi HC, Chen SL, Liao CJ etal. Thyroid hormone receptors promote metastasis of human hepatoma cells via regulation of TRAIL. Cell Death Differ. 2012; 19: 1802-1814.
67. Liao CH, Yeh CT, Huang YH etal. Dickkopf 4 positively regulated by the thyroid hormone receptor suppresses cell invasion in human hepatoma cells. Hepatology 2012; 55: 910-920.
68. Jia WD, Xu GL, Wang W etal. A somatostatin analogue, octreotide, inhibits the occurrence of second primary tumors and lung metastasis after resection of hepatocellular carcinoma in mice. Tohoku J. Exp. Med. 2009; 218: 155-160.
69. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract. Res. Clin. Gastroenterol. 2005; 19: 3-23.
70. Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J. Virol. 2004; 78: 12725-12734.
71. Zhang WY, Cai N, Ye LH, Zhang XD. Transformation of human liver LO2 cells mediated by stable HBx transfection. Acta Pharmacol. Sin. 2009; 30: 1153-1161.
72. Lara-Pezzi E, Majano PL, Yanez-Mo M etal. Effect of the hepatitis B virus HBx protein on integrin-mediated adhesion to and migration on extracellular matrix. J. Hepatol. 2001; 34: 409-415.
73. Xia LM, Huang WJ, Wu JG etal. HBx protein induces expression of MIG and increases migration of leukocytes through activation of NF-kappaB. Virology 2009; 385: 335-342.
74. Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J. 2004; 18: 1123-1125.
75. Zhang F, Wang Q, Ye L, Feng Y, Zhang X. Hepatitis B virus X protein upregulates expression of calpain small subunit 1 via nuclear factor-kappaB/p65 in hepatoma cells. J. Med. Virol. 2010; 82: 920-928.
76. Yoo Y-G, Na T-Y, Seo H-W etal. Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. Oncogene 2008; 27: 3405-3413.
77. Kong G, Zhang J, Zhang S, Shan C, Ye L, Zhang X. Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. PLoS ONE 2011; 6: e19518.
78. Li J, Lau GK, Chen L etal. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS ONE 2011; 6: e21816.
79. Zhang Y, Li Y, Ma Y etal. Dual effects of interleukin-18: inhibiting hepatitis B virus replication in HepG2.2.15 cells and promoting hepatoma cells metastasis. Am. J. Physiol. Gastrointest. Liver Physiol. 2011; 301: G565-573.
80. Jiang R, Tan Z, Deng L etal. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011; 54: 900-909.
81. Kubo F, Ueno S, Hiwatashi K etal. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann. Surg. Oncol. 2005; 12: 800-807.
82. Yang W, Wang C, Lin Y etal. OV6(+) tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma. J. Hepatol. 2012; 57: 613-620.